Loading
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Previous close
$26.76
−$0.40 · -1.47%
Regular session · ET · Market data may be delayed.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Day range
Current $26.76
52-week range
Current $26.76
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
15
Overpriced
Sentiment
75
Bullish
Risk
55
Elevated Risk
Momentum
59
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Day range
Current $26.76
52-week range
Current $26.76
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.94M USD | 9.04M USD | 14.02M USD | — | — |
| Cost of goods sold | 2.96M USD | — | — | — | — |
| Gross profit | 3.99M USD | 9.04M USD | 14.02M USD | — | — |
| Research and development | 174.33M USD | 129.54M USD | 23.09M USD | 23.27M USD | 14.11M USD |
| Selling, general, and administrative | 43.77M USD | 32.96M USD | 19.66M USD | 13.63M USD | 11.09M USD |
| Operating expenses | 218.1M USD | 314.84M USD | 123.55M USD | 36.9M USD | 25.2M USD |
| Interest income | 11.72M USD | 12.84M USD | 2.72M USD | 5K USD | 10K USD |
| Interest expense | — | — | — | 5K USD | 10K USD |
| Depreciation and amortization | 2.96M USD | 2.1M USD | 728K USD | 631K USD | 755K USD |
| Operating income | −214.11M USD | −305.8M USD | −109.53M USD | −36.9M USD | −25.2M USD |
| Net income | −212.39M USD | −292.96M USD | −106.81M USD | −36.9M USD | −24.71M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI86.66M0.75%11.49B USD0.35%$163.81-0.35%
Vanguard Morningstar Total Stock Market ETFVTI73.76M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM73.15M0.09%79.88B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF27.9M0.03%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO26.34M0.18%14.58B USD0.24%$377.54+0.12%
Schwab U.S. Small-Cap ETFSCHA13.93M0.06%22.56B USD0.03%$34.55+1.01%
Vanguard Russell 2000 ETFVTWO13.46M0.08%17.4B USD0.06%$119.62+0.25%
Tema Oncology ETFCANC6.31M2.90%216.51M USD0.99%$44.0502-0.70%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOTema Oncology ETFCANCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
